Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 3/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | PPIA | P62937 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28881534 | 0.86 | LMNA (0.48) | SMPD1HDAC1HDAC8HDAC6SMN1; SMN2 | |
| SCHEMBL3245222 | 0.85 | SMPD1 (0.67) | SMPD1HDAC1HDAC8HDAC6SMN1; SMN2 | |
| Bicarbonate SCHEMBL5504807 | 0.81 | SMPD1 (0.62) | SMPD1HDAC1HDAC8HDAC6SMN1; SMN2 | |
| Bicarbonate SCHEMBL5504809 | 0.81 | SMPD1 (0.62) | SMPD1HDAC1HDAC8HDAC6SMN1; SMN2 | |
| SCHEMBL18031233 | 0.80 | SMN1; SMN2 (0.60) | SMPD1HDAC1HDAC8HDAC6SMN1; SMN2 | |
| SCHEMBL23536758 | 0.80 | CA12 (0.48) | SMPD1HDAC6SMN1; SMN2HPGDNPC1 | |
| SCHEMBL17835716 | 0.80 | SMPD1 (0.62) | SMPD1HDAC1HDAC8HDAC6SMN1; SMN2 | |
| SCHEMBL15476283 | 0.80 | MEN1 (0.45) | SMPD1HDAC1HDAC8HDAC6SMN1; SMN2 | |
| SCHEMBL18660058 | 0.80 | SMN1; SMN2 (0.62) | SMPD1HDAC1HDAC8HDAC6SMN1; SMN2 | |
| SCHEMBL30820546 | 0.80 | SMN1; SMN2 (0.62) | SMPD1HDAC1HDAC8HDAC6SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260053796-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-12427144-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| CN-118059104-A | Compounds and methods for targeted degradation of androgen receptor | 阿尔维纳斯运营股份有限公司 | 2024-05-24 | — | — | CN | disclosed |
| US-20240131023-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2024-04-25 | — | — | US | disclosed |
| CN-115175901-B | Compounds and methods for targeted degradation of androgen receptor | 阿尔维纳斯运营股份有限公司 | 2024-03-22 | — | — | CN | disclosed |
| US-11883393-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-20210196710-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2021-07-01 | — | — | US | disclosed |
| US-20210196710-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2021-07-01 | — | — | US | disclosed |
| WO-2021127443-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260053796-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, NR5A1, KLK3 | SMPD1 3515/4885HDAC1 424/4885HDAC8 532/4885 |
| US-12427144-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, KLK3, ACP3 | SMPD1 1556/4885HDAC1 428/4885HDAC8 453/4885 |
| US-11883393-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, KLK3, ACP3 | SMPD1 1556/4885HDAC1 428/4885HDAC8 453/4885 |
| US-20210196710-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, KLK3, ACP3 | SMPD1 1556/4885HDAC1 428/4885HDAC8 453/4885 |
| US-20240131023-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, KLK3, ACP3 | SMPD1 1556/4885HDAC1 428/4885HDAC8 453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.